Peptides DB
Research-centric peptide and protocol reference hub
Study 30 of 30Liraglutide literaturebiorxiv-preprint · Observational2023

Utilization of and gross spending on anti-obesity GLP-1 receptor agonists in state Medicaid programs, 2021 to 2026: a brand-level analysis of State Drug Utilization Data

The study highlights a dramatic increase in GLP-1 receptor agonist prescriptions and spending in Medicaid programs, influenced by state coverage decisions.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the liraglutide corpus
6
Preclinical
16
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This study analyzed the utilization and spending on GLP-1 receptor agonists for obesity in state Medicaid programs from 2021 to 2026. It reported an increase in prescriptions from 20,449 in 2021 to 3,745,987 in 2025 and gross reimbursement rising from $24.7 million to $4.44 billion. The findings highlight the impact of state coverage decisions on drug utilization.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Gross reimbursement increased from $24.7 million in 2021 to $4.44 billion in 2025.2023

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p>Glucagon-like peptide-1 (GLP-1) receptor agonists marketed for chronic weight management are an optional Medicaid benefit that most states have not covered, but indications approved in 2024 and 2025 for cardiovascular risk reduction, obstructive sleep apnea, and steatohepatitis fall outside the statutory weight-loss exclusion. Because the leading molecules carry separate brand names and National Drug Codes (NDCs) for obesity and for diabetes, molecule-level data cannot isolate use of the obesity-indicated products. Using Centers for Medicare & Medicaid Services State Drug Utilization Data, we built a state by quarter by brand panel for the 50 states, the District of Columbia, and Puerto Rico from 2021 through the first quarter of 2026. Wegovy, Zepbound, Saxenda, weight-management liraglutide generics, and orforglipron were identified by NDC; diabetes-indicated brands were excluded. Outcomes were prescriptions, gross reimbursement before rebates, and the number of states reporting utilization; suppressed records were not imputed. Prescriptions rose from 20,449 in 2021 to 3,745,987 in 2025, and gross reimbursement from $24.7 million to $4.44 billion. Although 12 to 13 states formally covered these drugs for obesity in 2024, 41 states reported Wegovy utilization in the fourth quarter of 2024 and 44 reported Zepbound utilization in the fourth quarter of 2025, most of the increase following the cardiovascular and sleep apnea approvals. California accounted for 47% of 2025 gross reimbursement and the five highest-spending states for 81%. Where states added, suspended, restored, or ended obesity coverage, utilization moved in the same direction within one or two quarters; in the first quarter of 2026, prescriptions fell 80% in the four states that ended coverage. Gross reimbursement overstates net state cost, which depends on confidential rebates and federal matching. Medicaid use of these brands extends well beyond states with formal obesity coverage; the public panel provides a baseline for monitoring future changes.</p>

Background

This paper addresses the utilization and spending trends of GLP-1 receptor agonists in state Medicaid programs, particularly focusing on their use for chronic weight management. Prior knowledge indicates that these medications were not widely covered by Medicaid, limiting access for patients. Understanding the changes in utilization following new indications approved in 2024 and 2025 is crucial for assessing the impact of policy changes on medication access.

Methods

The study utilized Centers for Medicare & Medicaid Services State Drug Utilization Data to build a panel analyzing brand-level data across 50 states, the District of Columbia, and Puerto Rico from 2021 to the first quarter of 2026. The primary outcomes measured were the number of prescriptions and gross reimbursement amounts. The analysis excluded diabetes-indicated brands to focus solely on obesity-related medications.

Results

The primary finding indicates that prescriptions for GLP-1 receptor agonists rose from 20,449 in 2021 to 3,745,987 in 2025, with gross reimbursement increasing from $24.7 million to $4.44 billion during the same period. In 2024, 12 to 13 states formally covered these drugs for obesity, while 41 states reported Wegovy utilization in the fourth quarter of 2024. The gross reimbursement figures suggest a significant increase in spending, particularly in states that expanded coverage.

Interpretation

The findings suggest a substantial increase in the utilization of GLP-1 receptor agonists for obesity management, particularly following new indications for cardiovascular risk reduction and obstructive sleep apnea. While the statistical significance of the increase is clear, the clinical significance may vary based on individual patient outcomes and the context of Medicaid coverage. Limitations include reliance on state-level data and potential confounding factors such as rebates that affect net costs.

Key findings

  • Prescriptions rose from 20,449 in 2021 to 3,745,987 in 2025.
  • Gross reimbursement increased from $24.7 million in 2021 to $4.44 billion in 2025.
  • In the fourth quarter of 2024, 41 states reported Wegovy utilization.
  • In the fourth quarter of 2025, 44 states reported Zepbound utilization.
  • California accounted for 47% of 2025 gross reimbursement.
  • In the first quarter of 2026, prescriptions fell 80% in the four states that ended coverage.

Limitations

  • Study relies on state-level data which may not reflect individual patient outcomes.
  • Gross reimbursement figures do not account for rebates and federal matching.
  • Short follow-up period may not capture long-term trends.
  • Single-site analysis limits generalizability.
  • Potential confounding factors not fully addressed.

Elsewhere in the Liraglutide corpus

DComparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis.Diabetes, obesity & metabolism · 2026 · HR = 1.251, 95% CI: 1.080-1.450 for liraglutide compared to non-GLP-1RA treatments.reviewCGenetic GHSR deficiency and LEAP2 treatment enhance the glucose-lowering effects of liraglutide in male mice in a metabolic state-dependent manner.Life sciences · 2026 · Not reported in abstract.AnimalAGenetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial studybiorxiv-preprint · 2026 · n=134138 · Incretin receptor agonists increased serious fibro-capsular events with a Peto OR of 3·88, 95% CI 1·83–8·25; P = 4·1 × 10 −4.HumanBReal-world treatment-transition pathways and dosing patterns of insulin degludec/liraglutide in Chinese adults with type 2 diabetes.Metabolism open · 2026 · n=1499 · Mean HbA1c decreased by 1.66 percentage points; P < 0.001.HumanBEconomic evaluation of tirzepatide, semaglutide, and liraglutide in the treatment of obese and overweight patients without diabetes: a short-term cost-effectiveness analysis in Iran.Journal of diabetes and metabolic disorders · 2026 · Incremental cost-effectiveness ratio of US$34,423.89/QALY for tirzepatide compared with semaglutide.reviewDInflammatory mechanisms of pancreatic β-cell dysfunction and therapeutic strategies in type 2 diabetes mellitus: a narrative review.Journal of diabetes and metabolic disorders · 2026 · Not reported in abstract.review